What is it about?
Authors observed that acute toxicity observed after adenoviral vectors administration, which is characterized by activation of innate immune responses, elevations of cytokine levels, liver transaminase levels and thrombocytopenia, can be blunted by anti-TNFa treatment with the FDA-approved drug Enbrel. This approach may be used for improving the therapeutic index of Ad gene therapy for human clinical trials.
Featured Image
Photo by Paweł Czerwiński on Unsplash
Read the Original
This page is a summary of: Modulation of TNFα, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors, Gene Therapy, May 2006, Springer Science + Business Media,
DOI: 10.1038/sj.gt.3302792.
You can read the full text:
Resources
Contributors
The following have contributed to this page
